Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

Abstract Number: 0490 • ACR Convergence 2020
Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁴, Ritu Gill⁶, Hiroto Hatabu⁷, Mizuki Nishino⁷, Cynthia Crowson⁸, John Davis¹, William Robinson⁹, Tripta Rughwani⁹, Jeremy Sokolove¹⁰, Michael Weinblatt⁴, Nancy Shadick¹¹, Tracy J. Doyle¹² and Jeffrey Sparks¹¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Department of Radiology; Brigham and Women’s Hospital, Boston, ⁸Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Mountain View, CA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹²Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) has been shown to increase risk for RA-associated interstitial lung disease (RA-ILD). However, RA-related autoantibodies used in clinical…
Abstract Number: 1720 • ACR Convergence 2020
Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Hyoun-Ah Kim¹, Ryan Peterson², Gary Firestein³, David Boyle⁴, Jane Buckner⁵, Sylvia Posso⁶, Eddie James⁵, William Robinson⁷, Jaron Arbet², LauraKay Moss⁸, Roger Gilmore⁸, Lindsay Hartje⁸, Saman Barzideh⁸, Jennifer Seifert⁹, Navin Rao¹⁰, Frédéric Baribaud¹¹, Sunil Nagpal¹², Alyssa Johnson¹³, V Michael Holers¹⁴ and Kevin D. Deane¹⁵, ¹University of Colorado Anschutz Medical Campus and Ajou University School of Medicine, Aurora, CO, ²Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, ³University of California, San Diego, La Jolla, CA, ⁴UC San Diego, San Diego, CA, ⁵Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Stanford University, Palo Alto, CA, ⁸University of Colorado Anschutz Medical Campus, Aurora, CO, ⁹Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Janssen Reserach and Development, Spring House, PA, ¹³Janssen Research and Development, Spring House, PA, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ¹⁵2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…
Abstract Number: 0743 • ACR Convergence 2020
Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis
William Robinson¹, Chun Wu², Sarah Hu², Sean Connolly² and Sumanta Mukherjee², ¹Stanford University School of Medicine, Stanford, CT, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: ACPAs are sensitive, highly specific markers of RA. Current tests cannot differentiate ACPA+ RA subtypes. Fine-specificity ACPAs (FS) can distinguish between ACPA+ RA subtypes…
Abstract Number: 1721 • ACR Convergence 2020
Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Heinrich-Karl Greenblatt¹, Ted Mikuls², Jess Edison³, Marie Feser⁴, Mark Parish⁵, LauraKay Moss⁵, Elizabeth Mewshaw⁶ and Kevin D. Deane⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Nebraska Medical Center, Omaha, NE, ³Walter Reed National Military Medical Center, Bethesda, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Walter Reed National Military Medical Center, Bethesda, MD, ⁷2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Autoantibodies including rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPA) may be elevated during a period that can be termed ‘Pre-RA’. In…
Abstract Number: 0756 • ACR Convergence 2020
Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive
Joe Zhuo¹, Manasi Suryavanshi¹, Lawshia Priya², Vadim Khaychuk¹, John Vaile¹, Jing Cui³, Nancy Shadick⁴ and Michael Weinblatt³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Mu-Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: A strong genetic association between HLA-DRB1 alleles containing the shared epitope (SE) and RA has been described.1 The SE has been associated with ACPA…
Abstract Number: 2043 • ACR Convergence 2020
Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
Ravi Kumar¹, Niyaz Yoosuf², Sanjay Boddul², Christina Gerstner³, Sara Turcinov⁴, Anatoly Dubnovitsky⁵, Fredrik Wermeling², Karine Chemin⁶ and Vivianne Malmström⁷, ¹Division of Rheumatology, Department of Medicine, Stickholm, Stockholms Lan, Sweden, ²Division of Rheumatology, Department of Medicine, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, ⁶Division of Rheumatology, Department of Medicine, Stockholm, Stockholms Lan, Sweden, ⁷Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Citrulline (cit) autoimmunity is central in rheumatoid arthritis (RA), including both anti-citrulline protein antibodies (ACPA) and autoreactive CD4+ T cells. While the ACPA are…
Abstract Number: 0757 • ACR Convergence 2020
Sunlight Exposure, Sun-protective Behaviour, and Anti-citrullinated Protein Antibody Positivity: A General Population-based Study in Quebec, Canada
Naizhuo Zhao¹, Audrey Smargiassi², Ines Colmegna³, Marie Hudson⁴, Marvin Fritzler⁵ and Sasha Bernatsky⁶, ¹McGill University, Montreal, Canada, ²l’Université de Montréal, Montreal, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, Canada, ⁴Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ⁵Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Sunlight exposure has been associated with lower rheumatoid arthritis (RA) risk, but to our knowledge, no one has ever studied sunlight exposure and anti-citrullinated…
Abstract Number: 0758 • ACR Convergence 2020
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹, Vidyanand Anaparti¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].